Details for New Drug Application (NDA): 203924
✉ Email this page to a colleague
NDA 203924 describes PRIMAQUINE PHOSPHATE, which is a drug marketed by Alvogen, Bayshore Pharms Llc, and Novast Labs, and is included in three NDAs. It is available from five suppliers. Additional details are available on the PRIMAQUINE PHOSPHATE profile page.
The generic ingredient in PRIMAQUINE PHOSPHATE is primaquine phosphate. There are four drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the primaquine phosphate profile page.
The generic ingredient in PRIMAQUINE PHOSPHATE is primaquine phosphate. There are four drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the primaquine phosphate profile page.
Summary for 203924
| Tradename: | PRIMAQUINE PHOSPHATE |
| Applicant: | Alvogen |
| Ingredient: | primaquine phosphate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 203924
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 15MG BASE | ||||
| Approval Date: | Feb 3, 2014 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
